New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
- PMID: 36108076
- DOI: 10.1210/clinem/dgac541
New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Erratum in
-
Correction to "New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease".J Clin Endocrinol Metab. 2022 Oct 20:dgac607. doi: 10.1210/clinem/dgac607. Online ahead of print. J Clin Endocrinol Metab. 2022. PMID: 36264677 No abstract available.
Abstract
The status of lipoprotein (a) [Lp(a)] as a cardiovascular risk factor has been resurrected by advances in genetics. Mendelian randomization studies show a causal link of Lp(a) with coronary artery disease (CAD), peripheral artery disease (PAD), and calcific aortic valve stenosis (CAVS). The genetics of Lp(a) is complex and extends beyond the kringle-IV type 2, as it is also dependent on ancestry. The plasma concentration of Lp(a) is determined by the hepatic production of apolipoprotein(a) [apo(a)] component of Lp(a), supporting the use of nucleic acids that inhibit the messenger RNA (mRNA) gene transcript for apo(a). Analytical barriers to measurement of Lp(a) are being addressed using isoform independent assays and a traceable standard. The association of Lp(a) and atherosclerotic cardiovascular disease is higher for myocardial infarction than PAD and CAVS. Increased risk of type 2 diabetes mellitus associated with low Lp(a) levels is perplexing and requires further investigation. The greatest advancement in Lp(a)-lowering therapies is based on using RNA therapeutics that are now being investigated in clinical trials. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition lowers Lp(a) modestly, but whether cardiovascular benefit is independent of low-density lipoprotein lowering remains unclear. Opportunistic and selective testing for Lp(a) is supported by moderate evidence, with the case for universal screening premature. Modification of behavioral and clinical risk factors may be targeted to mitigate Lp(a)-mediated risk of cardiovascular disease. Clinical practice guidelines have been developed to address gaps in care of high Lp(a), but full implementation awaits the findings of clinical outcome trials using RNA-directed therapies currently underway.
Keywords: Lp(a); Lp(a) screening; Lp(a) treatment; cardiovascular disease; lipoprotein (a); risk factor.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses.Circ Genom Precis Med. 2021 Aug;14(4):e003271. doi: 10.1161/CIRCGEN.120.003271. Epub 2021 Jul 19. Circ Genom Precis Med. 2021. PMID: 34279996
-
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes.J Am Coll Cardiol. 2019 Dec 17;74(24):2982-2994. doi: 10.1016/j.jacc.2019.10.019. Epub 2019 Dec 9. J Am Coll Cardiol. 2019. PMID: 31865966
-
Lipoprotein (a): When to Measure and How to Treat?Curr Atheroscler Rep. 2021 Jul 8;23(9):51. doi: 10.1007/s11883-021-00951-2. Curr Atheroscler Rep. 2021. PMID: 34235598 Review.
-
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.JAMA Cardiol. 2022 Jul 1;7(7):760-769. doi: 10.1001/jamacardio.2022.0987. JAMA Cardiol. 2022. PMID: 35583875 Review.
-
Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis.JACC Basic Transl Sci. 2020 Aug 26;5(9):888-897. doi: 10.1016/j.jacbts.2020.06.012. eCollection 2020 Sep. JACC Basic Transl Sci. 2020. PMID: 33015412 Free PMC article.
LinkOut - more resources
Full Text Sources
Miscellaneous